Ticagrelor-Induced Pneumonitis and Subsequent Pulmonary Hemorrhage;Drug Rash with Eosinophilia Due to Boceprevir;Hepatitis C Reactivation after Starting Infliximab;Hydralazine-Associated Immune Glomerulonephritis;Fluoroquinolones and Retinal Detachment
Restricted accessResearch articleFirst published online June, 2014
Ticagrelor-Induced Pneumonitis and Subsequent Pulmonary Hemorrhage;Drug Rash with Eosinophilia Due to Boceprevir;Hepatitis C Reactivation after Starting Infliximab;Hydralazine-Associated Immune Glomerulonephritis;Fluoroquinolones and Retinal Detachment
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers.
Get full access to this article
View all access options for this article.
References
1.
WhitmoreTJ, O'SheaJP, StaracD, A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor. Chest. 2014;145(3):639–641.
2.
SamainA, Duval-ModesteAB, JolyP, First case of drug rash eosinophilia and systemic symptoms due to boceprevir. J Hepatol. 2014;60:891–893.
3.
HuangM, HuangL.Reactivation of hepatitis C viral infection after treatment with infliximab. J Clin Gastroenterol. 2014;48(2):189.
KuoSC, ChenYT, LeeYT, Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: A population-based cohort study. Clin Infect Dis. 2014;58(2):197–203.
6.
EtminanM, ForooghianF, BrophyJM, Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307:1414–1419.
